AiCure

Articles Published in 2012

Catalent, UMN Pharma collaborate on biosimilar development, production in Japan

Monday, December 17, 2012 11:35 AM

Catalent Pharma Solutions, a Somerset, N.J.-based developer of solutions and drug delivery technology, has signed an agreement to provide UMN Pharma, a Japanese pharmaceutical company, a broad range of biosimilar cell lines using Catalent's proprietary GPEx technology.

More... »


Warnex completes sale of bioanalytical services to CRO Biotrial

Monday, December 17, 2012 11:06 AM

Warnex, a life sciences company, has successfully completed the sale of its bioanalytical services division to Biotrial Research, a privately-owned CRO headquartered in France.

More... »


Thiel Foundation’s Breakout Labs awards three new grants

Friday, December 14, 2012 02:03 PM

The Thiel Foundation has announced three new grants awarded to AVEtec, General Genomics, and Siva Therapeutics through Breakout Labs, its revolving fund to promote innovation in science and technology.

More... »

Fresenius to discontinue biotech subsidiary

Friday, December 14, 2012 01:27 PM

Fresenius, a health care group with international operations, has decided to discontinue its subsidiary Fresenius Biotech. Instead, the company will focus on its four established business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, which offer significant growth opportunities.

More... »

Bayer submits NDA for radium Ra 223 dichloride for castration-resistant prostate cancer

Friday, December 14, 2012 12:07 PM

Bayer HealthCare has submitted a New Drug Application (NDA) to the FDA seeking approval for radium Ra 223 dichloride (radium-223), a fast tracked investigational compound for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.

More... »

Lilly discontinues 1 of 3 phase III rheumatoid arthritis registration studies for tabalumab

Friday, December 14, 2012 11:40 AM

Global pharmaceutical company Eli Lilly is halting one of three phase III rheumatoid arthritis (RA) registration studies of tabalumab, an anti-BAFF monoclonal antibody, due to insufficient efficacy.

More... »

Biocartis completes $44.5M series D funding

Friday, December 14, 2012 11:12 AM

Biocartis, a molecular diagnostics company developing and commercializing high quality, easy to use platforms and clinically relevant oncology assays, has completed a $44.5 million Series D equity funding entirely backed by existing investors.

More... »

Eisai, UCL form drug discovery alliance for neurological diseases

Friday, December 14, 2012 10:43 AM

Eisai, a pharmaceutical company based in Toyko, and University College London (UCL) have entered into a new agreement to establish a major drug discovery and development collaboration investigating new ways of treating neurological diseases such as Alzheimer’s disease, Parkinson’s disease and other related disorders.

More... »

The Medicines Company to acquire Incline Therapeutics

Friday, December 14, 2012 10:14 AM

The Medicines Company, a medical solutions company based in Parsippany, N.J., has agreed to acquire Incline Therapeutics, hospital-focused specialty pharmaceutical company based in Redwood City, Calif.

More... »

U.K.’s MRC invests over $17M in stratified medicine research

Thursday, December 13, 2012 08:00 AM

The U.K.’s Medical Research Council (MRC) plans to invest $17.1 million in three major new collaborations that will advance the emerging field of stratified medicine—investigating why different patients with the same diagnosis respond differently to treatments.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs